

FRESENIUS | Factsheet Q1 – Q3/2023

COMPANY PROFILE

Fresenius is a global healthcare group. We offer system-critical products and services for leading therapies for care of critically and chronically ill patients. The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios and the Investment Companies Fresenius Medical Care (in accordance with IFRS 5) and Fresenius Vamed.

FRESENIUS GROUP IN FIGURES

| € in millions | Q1–3/23 | Q1–3/22 | Change | FY/22 |
|---|---------|---------|--------|---------|
| Revenue and Earnings | | | | |
| Revenue ¹ | 16,621 | 15,862 | 5% | 21,532 |
| EBIT ^{1,2} | 1,628 | 1,631 | 0% | 2,190 |
| Net income ^{2,3} | 1,108 | 1,284 | -14% | 1,729 |
| Earnings per share in € ^{2,3} | 1.97 | 2.29 | -14% | 3.08 |
| Balance sheet and cash flow | | | | |
| Total assets | 75,328 | | | 76,400 |
| Non-current assets | 30,493 | | | 58,121 |
| Equity ⁴ | 30,282 | | | 32,218 |
| Equity ratio ⁴ | 40.2% | | | 42.2% |
| Net debt/EBITDA ^{1,2,5} | 4.03x | | | 3.80x |
| Investments ⁶ | 922 | 1,497 | -38% | 2,015 |
| Operating cash flow ¹ | 859 | 806 | 7% | 2,031 |
| Operating cash flow in % of sales | 5.2% | 5.1% | | 9.4% |
| Profitability | | | | |
| EBIT margin ^{1,2} | 9.8% | 10.3% | | 10.2% |
| Return on equity after taxes (ROE) ^{1,2,3} | 7.8% | 8.4% | | 8.5% |
| Return on operating assets (ROOA) ^{1,2} | 5.6% | | | 6.1% |
| Return on invested capital (ROIC) ^{1,2} | 5.0% | | | 5.6% |
| Employees ¹ | 193,527 | | | 188,876 |

¹ From continuing operations; FMC to be deconsolidated

² Before special items


³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

⁴ Including noncontrolling interests

⁵ At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items; including lease liabilities, including FME dividend

⁶ Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE



¹ FMC to be deconsolidated

OPERATING COMPANIES

| € in millions | | Q1–3/23 | Q1–3/22 | Change | FY/22 |
|---------------|-------------------|---------|---------|--------|--------|
| | Revenue | 6,013 | 5,814 | 3% | 7,850 |
| | EBIT ¹ | 863 | 844 | 2% | 1,080 |
| | Revenue | 9,132 | 8,685 | 5% | 11,716 |
| | EBIT ¹ | 861 | 831 | 4% | 1,185 |


¹ Before special items

INVESTMENT COMPANY

| € in millions | | Q1–3/23 | Q1–3/22 | Change | FY/22 |
|---------------|-------------------|---------|---------|--------|-------|
| | Revenue | 1,761 | 1,647 | 7% | 2,359 |
| | EBIT ¹ | -37 | 29 | -- | 20 |

¹ Before special items


REVENUE BY REGION



Q1–3/23: €16.6 billion

- ▶ **Fresenius Kabi** specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids.
- ▶ **Fresenius Helios** is Europe's leading private health care provider. The company comprises Helios Germany, Helios Spain and Helios Fertility. Helios Germany operates 86 hospitals, around 240 outpatient centers, 27 occupational health centers and 6 prevention centers. Helios Spain operates 50 hospitals, around 100 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with 8 hospitals and as a provider of medical diagnostics. Helios Fertility offers a wide spectrum of state-of-the-art services in the field of fertility treatments.
- ▶ **Fresenius Vamed** internationally manages projects and provides services for hospitals and other health care facilities and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, design planning, medical and hospital engineering as well as construction, via maintenance and technical management to total operational management and high-end services.


REVENUE BY BUSINESS SEGMENT




Q1–3/23: €16.6 billion

FRESENIUS | Factsheet Q1 – Q3/2023

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT OF DIVIDENDS IN €



GROUP OUTLOOK 2023

| | FY/22 Base | Targets 2023 |
|---|-----------------|---------------------------|
| Revenue, growth (organic) excl. FMC | €21,532 million | Mid single-digit %-growth |
| EBIT growth ¹ (cc) excl. FMC | €2,190 million | Broadly flat development |

¹ Before special items

For the outlook of the business segments please see the Investor News of November 2, 2023.

FRESENIUS SHARE / ADR

| | Share |
|--|---------------|
| Securities code no. | 578 560 |
| ISIN | DE0005785604 |
| Ticker symbol | FRE |
| ADR CUSIP | 35804M105 |
| ADR Ticker symbol | FSNUY |
| Number of shares (September 30, 2023) | 563,237,277 |
| Market capitalization (September 30, 2023) | €14.3 billion |

ANALYST RECOMMENDATIONS


Equal-weight/ Hold/
Neutral **28%**



Buy/Outperform/
Overweight **72%**

As of November 1, 2023

FINANCING MIX OF THE FRESENIUS GROUP



September 30, 2023: ~€15.1 billion

FINANCIAL CALENDAR

| | Dates |
|--------------------------------|-------------------|
| Report on Fiscal Year 2023 | February 21, 2024 |
| Report on 1st quarter 2024 | May 8, 2024 |
| Annual General Meeting | May 17, 2024 |
| Report on 1st half 2024 | July 31, 2024 |
| Report on 1st–3rd quarter 2024 | November 6, 2024 |

Please note that these dates could be subject to modifications.
www.fresenius.com/events-and-roadshows

CONTACT



Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.de

Markus Georgi
Senior Vice President
Investor Relations
Telephone: +49 (0) 61 72/6 08-24 85
Telefax: +49 (0) 61 72/6 08-24 88

Follow us on Social Media:

[linkedin.com/company/fresenius-investor-relations](https://www.linkedin.com/company/fresenius-investor-relations)
 twitter.com/Fresenius_IR

For more information please see the imprint on our corporate website.